A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
Public ClinicalTrials.gov record NCT04992312. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
Study identification
- NCT ID
- NCT04992312
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Interventions
- Glucagon Nasal Powder [Baqsimi] Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 4 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2022
- Primary completion
- Nov 4, 2023
- Completion
- Nov 4, 2023
- Last update posted
- May 22, 2024
2022 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nemours Childrens Clinic | Jacksonville | Florida | 32207 | — |
| St. Luke's Regional Medical Center | Boise | Idaho | 83712 | — |
| Riley Hospital for Children | Indianapolis | Indiana | 46202 | — |
| University of Minnesota Medical School | Minneapolis | Minnesota | 55454 | — |
| Children's Mercy Hospital | Kansas City | Missouri | 64108 | — |
| UBMD Pediatrics | Buffalo | New York | 14203 | — |
| Cincinnati Childrens Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04992312, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04992312 live on ClinicalTrials.gov.